MindMed's LSD tartrate receives breakthrough therapy designation from the FDA for the treatment of generalized anxiety disorder. GAD affects a significant portion of the US population, with high costs ...

A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder, Mind Medicine Inc. announced ...

Add Yahoo as a preferred source to see more of our stories on Google. This photo provided by Catalent shows Catalent's MindMed's formulation of LSD. (Catalent via AP) WASHINGTON (AP) — LSD reduced ...

LSD reduced symptoms of anxiety in a midstage study published Thursday, paving the way for additional testing and possible medical approval of a psychedelic drug that has been banned in the U.S. for ...

MindMed Inc. said Tuesday it’s on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of ...

The improvements happened without any therapy done during the patients’ trip TUESDAY, Sept. 9, 2025 (HealthDay News) — "Flower power" psychedelic drugs might be a potential cure for modern anxiety, ...

Encouraging outcomes from a clinical study on the LSD-analog substance MM120, or lysergide d-tartrate, have led the Food and Drug Administration (FDA) to designate it as a “breakthrough therapy” for ...

Mind Medicine Inc.’s stock jumped 51.5% on Thursday after the biotech company said the Food and Drug Administration has granted breakthrough designation for its MM120 LSD-based treatment for ...

Scientists in Switzerland are testing the anxiety-lowering effects of LSD on people near death, and are reporting promising results. A new study published in The Journal of Nervous and Mental Disease ...